CHA
TBPH icon

Carmichael Hill & Associates’s Theravance Biopharma TBPH Stock Holding History

Carmichael Hill & Associates’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40
Closed -$1K – 782
2020
Q4 		$1K Hold
40
– – ﹤0.01% 722
2020
Q3 		$1K Buy
40
+20
+100% +$375 ﹤0.01% 697
2020
Q2 		$0 Buy
+20
New +$514 ﹤0.01% 722

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Carmichael Hill & Associates's TBPH Position: Q1 2021 in Review

Carmichael Hill & Associates sold out of Theravance Biopharma (TBPH) in Q1 2021, closing a stake of 40 shares — an estimated $1K sold.

Carmichael Hill & Associates first reported a position in TBPH in Q2 2020 and held it in 3 quarters. The position peaked at $1K in Q4 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q1 2021.

  • Carmichael Hill & Associates reported no remaining Theravance Biopharma position as of Q1 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 40 Theravance Biopharma shares in Q1 2021, an estimated $1K.
  • Carmichael Hill & Associates first reported a position in Theravance Biopharma in Q2 2020 and held it in 3 quarters.
  • Carmichael Hill & Associates's Theravance Biopharma position peaked at $1K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2021.

Based on Carmichael Hill & Associates's 13F filing for Q1 2021, filed 28 Apr 2021.